Biofrontera
WOBURN, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the pr
Key facts
- Headquarters
- WOBURN, Massachusetts, United States
- Employees
- 70
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (BFRI)
- Website
- www.biofrontera.com
- Company page
Recent activity at Biofrontera
- : SEC 8-K (8.01): On September 14, 2026, Biofrontera Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application concerning Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%. The approval facilitates the use of this drug in conjunction with photodynamic therapy. This significant development could enhance the company's product offerings in dermatological treatments, potentially increasing market share and revenue. The FDA's notification represents a critical milestone in the regulatory process for the company's product expansion strategy.
- : SEC 8-K (1.01): On November 6, 2025, Biofrontera Inc. entered into an Asset Purchase Agreement (APA) with Pelthos Therapeutics Inc. for the sale of all assets relating to a specific business segment. This agreement represents a significant strategic step for Biofrontera Inc., allowing them to streamline operations and focus on core areas. The financial details regarding the transaction value have not been disclosed, but this agreement is expected to enhance Biofrontera's market position. The closing date noted is crucial as it indicates the timeline for the transaction's effectivity and subsequent integration processes.
- : SEC 8-K (2.01): On October 23, 2025, Biofrontera Inc. announced the completion of its restructuring and asset purchase agreement with Biofrontera AG. This transaction was supported by an $11 million investment led by existing investors, suggesting a strong backing for the company's restructuring efforts. The asset purchase is anticipated to enhance Biofrontera Inc.'s operational capabilities and market position. Details regarding the specific assets acquired were not disclosed in the summary, but the involvement of significant existing investors indicates strategic confidence in the company's future direction.
- : SEC 8-K (1.01): On October 20, 2025, Biofrontera Inc. entered into a Material Definitive Agreement with Biofrontera AG, comprising an Asset Purchase Agreement and an Earnout Agreement. This strategic transaction indicates a significant asset acquisition aimed at enhancing Biofrontera Inc.'s operational capabilities. The financial details, including specific amounts involved in the agreements, have not been disclosed in the filing. The arrangement is expected to strengthen Biofrontera's position in the market and potentially lead to future revenue increases based on the performance metrics outlined in the Earnout Agreement.
- : Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
- : Biofrontera
- : Biofrontera
- : Biofrontera
- : Biofrontera
- : Biofrontera
Biofrontera funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Venture | $11.0M |
| Dec 2024 | Seed | $4.2M |
| Mar 2024 | Venture | $8.0M |
| Nov 2022 | Seed | $3.7M |
| Aug 2022 | Venture | $7.1M |
Leadership
- John Borer, Director
- Beth Hoffman, Director
- Hermann Luebbert, Executive Officer, Director
- Kevin Weber, Director
- Loretta Wedge, Director
- John Borer, Director
- Beth Hoffman, Director
- Hermann Luebbert, Executive Officer, Director
- Loretta Wedge, Director
- George Jones, Chief Commercial Officer
- Jayna Gonzales, Human Resources Director
- Fred Leffler, Chief Financial Officer
Verified email and direct lines for Biofrontera’s decision-makers are on Fundz. See plans
Employee benefit plans
Biofrontera files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Feb 2027.
Biofrontera in the news
- PTA-News: Biofrontera AG: Biofrontera veröffentlicht Ergebnisse für das erste Halbjahr 2026 - TradingView (Sep 30, 2026)
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma - GlobeNewswire (Sep 14, 2026)
- PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG - TradingView (Sep 30, 2026)
- PTA-AFR: Biofrontera AG: Pre-announcement of a financial report according to articles 114 - 117 WpHG - TradingView (Sep 30, 2026)
- Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewswire (Aug 05, 2026)
- Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update - Yahoo Finance (May 14, 2026)
- Biofrontera Completes Enrollment and Active Treatment Phase in Phase 3 Ameluz PDT Trial for AK on the Body - Dermatology Times (Sep 16, 2025)
- Transcript: Biofrontera Q2 2026 Earnings Conference Call - Benzinga (Sep 28, 2026)
Companies similar to Biofrontera
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Lipella Pharmaceuticals · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Galmed Pharmaceuticals Ltd · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- EyePoint Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About Biofrontera: questions and answers
What does Biofrontera do?
Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the pr
Where is Biofrontera headquartered?
Biofrontera is headquartered in WOBURN, Massachusetts, United States.
How many employees does Biofrontera have?
Biofrontera has about 70 employees.
Has Biofrontera raised funding?
Yes. Fundz has recorded 5 funding events for Biofrontera. The most recent, $11.0M, was in Jul 2025.
What is the latest news on Biofrontera?
On Sep 14, 2026, SEC 8-K (8.01): On September 14, 2026, Biofrontera Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application concerning Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%. The approval facilitates the use of this
Is Biofrontera a public company?
Yes. Biofrontera is publicly traded under the ticker BFRI.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy